August 18, 2014 | According to a “Globes” report, Novartis AG will acquire Gamida Cell, a developer of stem cell therapies including one for the treatment of blood cancer. The deal, which was previously called off, is back on, but will not involve an exit of millions of dollars and instead will occur in stages of investment from Novartis. Later in the process, Gamida Cell shareholders are expected to sell their holdings for a large sum. However, the deal still remains subject to the completion of Gamida Cell’s product NiCord, a blood cancer treatment. Gamida Cell is headed by CEO Dr. Yael Margolin.